- Home
- LXP vs XENE Comparison
LXP vs XENE Comparison
Compare LXP & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- XENE
- Stock Information
- Founded
- LXP 1993
- XENE 1996
- Country
- LXP United States
- XENE Canada
- Employees
- LXP N/A
- XENE N/A
- Industry
- LXP Real Estate Investment Trusts
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- XENE Health Care
- Exchange
- LXP Nasdaq
- XENE Nasdaq
- Market Cap
- LXP 2.6B
- XENE 3.1B
- IPO Year
- LXP 1993
- XENE 2014
- Fundamental
- Price
- LXP $46.12
- XENE $40.80
- Analyst Decision
- LXP Buy
- XENE Strong Buy
- Analyst Count
- LXP 3
- XENE 10
- Target Price
- LXP $10.83
- XENE $52.90
- AVG Volume (30 Days)
- LXP 863.5K
- XENE 813.9K
- Earning Date
- LXP 10-30-2025
- XENE 11-03-2025
- Dividend Yield
- LXP 6.09%
- XENE N/A
- EPS Growth
- LXP 487.66
- XENE N/A
- EPS
- LXP 1.90
- XENE N/A
- Revenue
- LXP $364,335,000.00
- XENE $7,500,000.00
- Revenue This Year
- LXP N/A
- XENE N/A
- Revenue Next Year
- LXP $3.89
- XENE $207.88
- P/E Ratio
- LXP $24.25
- XENE N/A
- Revenue Growth
- LXP 6.98
- XENE N/A
- 52 Week Low
- LXP $34.25
- XENE $26.74
- 52 Week High
- LXP $52.52
- XENE $44.23
- Technical
- Relative Strength Index (RSI)
- LXP 92.49
- XENE 54.43
- Support Level
- LXP $44.17
- XENE $39.04
- Resistance Level
- LXP $52.52
- XENE $40.50
- Average True Range (ATR)
- LXP 1.05
- XENE 1.48
- MACD
- LXP 4.41
- XENE -0.14
- Stochastic Oscillator
- LXP 85.18
- XENE 64.28
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.